Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PTT-006
- Development stage
- Preclinical
- Lead developer
- Pyrotech Therapeutics
- Modality
- Small Molecules
01
Overview
PTT-006 is a small molecule drug candidate currently in the early discovery stage of development by Pyrotech Therapeutics. It is being investigated for the treatment of immune system diseases, specifically inflammatory bowel disease (IBD) and asthma. The drug is part of Pyrotech's proprietary platform focused on discovering first-in-class innate immune modulators. PTT-006 is designed to modulate pyroptosis and innate immunity pathways, which are critical drivers of chronic inflammation. By regulating these pathways, the candidate aims to provide a novel therapeutic approach for patients suffering from respiratory and gastrointestinal inflammatory conditions.
Beyond the preview
Go deeper on PTT-006.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PTT-006.